MaaT 034
Alternative Names: MaaT-034Latest Information Update: 25 Sep 2024
At a glance
- Originator MaaT Pharma
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 19 Sep 2024 MaaT Pharma plans first in human clinical trial for Solid tumours in 2026
- 07 May 2024 MaaT Pharma anticipates to select a candidate for clinical development, in 1H of 2024
- 08 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours were presented at the American Association for Cancer Research Annual Meeting 2024 (AACR-2024)